Salín-Pascual RJ, Upadhyaya U, Shiromani PJ

Language: Spanish
References: 56
Page: 184-194
PDF size: 172.69 Kb.

ABSTRACT

Introduction: A series of physiological changes occur in the cycle of sleep and wakefulness throughout the life of animals and humans. They can be linked to changes in neurotransmission systems in the number of cells that are the mechanisms regulating the phases of sleep and waking. The changes of sleep in the healthy elderly are similar to those reported in primary or psychophysiological insomnia. The possibility that the system of neurotransmission of the purine, adenosine, is involved in these changes was investigated in this paper where we used an animal model. F344 rats, males were evaluated with sleep logs and challenges with caffeine and vehicle. Material and methods: We studied three groups of animals: young rats (three months), adult rats (10 months) and old rats (20 months) (N = 10 per group). They were operated and fixed electrodes were placed in the skull and neck muscles to record chronic sleep. A week later, it was proceeded to record the baseline and then proceeded to the pilot phase. This was done in two stages of experiments. Administration of caffeine without sleep deprivation and administration of caffeine with sleep deprivation. Injections of caffeine (IP) in two doses (10 and 20 mg/kg) or vehicle (saline) were made in all animals, with a week of separation maneuver. The injections were made at the beginning of the light phase (7:00 h more sleep phase in rats) or dark phase (19:00 h phase of increased activity). Besides, the three groups were subjected to sleep deprivation, and the administration of caffeine and placebo (this only during the beginning of darkness).ResultsThe old rats were more sensitive to the type of stimulant effect of caffeine in both cases of injection into the darkness or brightness, plus the pressure generated by the dream of sleep deprivation with caffeine was inhibited in both dose groups in adult and old rats, but not the same thing happened in the youth who presented sleep rebound during the dark of an independent in the dose of caffeine. Conclusion: This could indicate ontogenic changes in the system to adenosine receptors, and that these may be in decline in the number of these receptors or the mechanisms of second messengers.

REFERENCES

1. Bephage G. Promoting quality sleep in older people: the nursing care role. Br J Nurs 2005; 14(4): 205-10.

2. Kloppel S, Kovacs GG, Voigtlander T, Wanschitz J, et al. Serotonergic nuclei of the raphe are not affected in human ageing. Neuroreport 2001; 12(4): 669-71.

3. Rocha FL, Uchoa E, Guerra HL, Firmo JO, et al. Prevalence of sleep complaints and associated factors in community-dwelling older people in Brazil: the Bambui Health and Ageing Study (BHAS). Sleep Med 2002; 3(3): 231-8.

4. Rumble R, Morgan K. Hypnotics, sleep, and mortality in elderly people. J Am Geriatr Soc 1992; 40(8): 787-91.

5. Sharma VK, Saxena MS. Climacteric symptoms: a study in the Indian context. Maturitas 1981; 3(1): 11-20.

6. Greco MA, Lu J, Wagner D, Shiromani PJ. c-Fos expression in the cholinergic basal forebrain after enforced wakefulness and recovery sleep. Neuroreport 2000; 11(3): 437-40.

7. Lu J, Shiromani P, Saper CB. Retinal input to the sleep-active ventrolateral preoptic nucleus in the rat. Neuroscience 1999; 93(1): 209-14.

8. Lu J, Greco MA, Shiromani P, Saper CB. Effect of lesions of the ventrolateral preoptic nucleus on NREM and REM sleep. J Neurosci 2000; 20(10): 3830-42.

9. Shiromani PJ, Schwartz WJ. Towards a molecular biology of the circadian clock and sleep of mammals. Adv Neuroimmunol 1995; 5(2): 217-30.

10. Achermann P. The two-process model of sleep regulation revisited. Aviat Space Environ Med 2004; 75(3 Suppl.): A37-A43.

11. Alexander SP. Flavonoids as antagonists at A1 adenosine receptors. Phytother Res 2006; 20(11): 1009-12.

12. Szymusiak R, Gvilia I, McGinty D. Hypothalamic control of sleep. Sleep Med 2007; 8(4): 291-301.

13. McCarley RW. Neurobiology of REM and NREM sleep. Sleep Med 2007; 8(4): 302-30.

14. Elmenhorst D, Meyer PT, Winz OH, Matusch A, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci 2007; 27(9): 2410-15.

15. Heller HC. A global rather than local role for adenosine in sleep homeostasis. Sleep 2006; 29(11): 1382-3.

16. Blanco-Centurion C, Xu M, Murillo-Rodriguez E, Gerashchenko D, et al. Adenosine and sleep homeostasis in the Basal forebrain. J Neurosci 2006; 26(31): 8092-100.

17. az-Munoz M, Hernandez-Munoz R, Suarez J, Vidrio S, et al. Correlation between blood adenosine metabolism and sleep in humans. Sleep Res Online 1999; 2(2): 33-41.

18. Chagoya DSV. Circadian variations of adenosine and of its metabolism. Could adenosine be a molecular oscillator for circadian rhythms? Can J Physiol Pharmacol 1995; 73(3): 339-55.

19. Retey JV, Adam M, Khatami R, Luhmann UF, et al. A Genetic Variation in the Adenosine A(2A) Receptor Gene (ADORA2A) Contributes to Individual Sensitivity to Caffeine Effects on Sleep. Clin Pharmacol Ther 2007; 81(5): 692-8.

20. Hong ZY, Huang ZL, Qu WM, Eguchi N, et al. An adenosine A receptor agonist induces sleep by increasing GABA release in the tuberomammillary nucleus to inhibit histaminergic systems in rats. J Neurochem 2005; 92(6): 1542-9.

21. Greene R, Siegel J. Sleep: a functional enigma. Neuromolecular Med 2004; 5(1): 59-68.

22. Stenberg D, Litonius E, Halldner L, Johansson B, et al. Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J Sleep Res 2003; 12(4): 283-90.

23. Porkka-Heiskanen T, Kalinchuk A, Alanko L, Urrila A, et al. Adenosine, energy metabolism, and sleep. ScientificWorldJournal 2003; 3: 790-8.

24. Porkka-Heiskanen T, Strecker RE, McCarley RW. Brain site-specificity of extracellular adenosine concentration changes during sleep deprivation and spontaneous sleep: an in vivo microdialysis study. Neuroscience 2000; 99(3): 507-17.

25. Mendelson WB. Effects of microinjections of triazolam into the ventrolateral preoptic area on sleep in the rat. Life Sci 1999; 65(25): L301-L307.

26. Mendelson WB. Sleep-inducing effects of adenosine microinjections into the medial preoptic area are blocked by flumazenil. Brain Res 2000; 852(2): 479-81.

27. Yakel JL, Warren RA, Reppert SM, North RA. Functional expression of adenosine A2b receptor in Xenopus oocytes. Mol Pharmacol 1993; 43(2): 277-80.

28. Thakkar MM, Delgiacco RA, Strecker RE, McCarley RW. Adenosinergic inhibition of basal forebrain wakefulness-active neurons: a simultaneous unit recording and microdialysis study in freely behaving cats. Neuroscience 2003; 122(4):1107-13.

29. Meerlo P, Roman V, Farkas E, Keijser JN, et al. Ageing-related decline in adenosine A1 receptor binding in the rat brain: an autoradiographic study. J Neurosci Res 2004; 78(5): 742-8.

30. Murillo-Rodriguez E, Blanco-Centurion C, Gerashchenko D, Salin- Pascual RJ, et al. The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience 2004; 123(2): 361-70.

31. Conde SV, Obeso A, Vicario I, Rigual R, et al. Caffeine inhibition of rat carotid body chemoreceptors is mediated by A2A and A2B adenosine receptors. J Neurochem 2006; 98(2): 616-28.

32. Ferretti V, Pretto L, Tabrizi MA, Bertolasi V. A structural study of new potent and selective antagonists to the A2B adenosine receptor. Acta Crystallogr B 2005; 61(Pt 5): 569-76

33. Kuzmin A, Johansson B, Gimenez L, Ogren SO, et al. Combination of adenosine A1 and A2A receptor blocking agents induces caffeinelike locomotor stimulation in mice. Eur Neuropsychopharmacol 2006; 16(2): 129-36.

34. Schwierin B, Borbely AA, Tobler I. Effects of N6-cyclopentyladenosine and caffeine on sleep regulation in the rat. Eur J Pharmacol 1996; 300(3): 163-7135. Landolt HP, Dijk DJ, Gaus SE, Borbely AA. Caffeine reduces lowfrequency delta activity in the human sleep EEG. Neuropsychopharmacology 1995; 12(3): 229-38.36. Landolt HP, Werth E, Borbely AA, Dijk DJ. Caffeine intake (200 mg) in the morning affects human sleep and EEG power spectra at night. Brain Res 1995; 675(1-2):67-74

35. Landolt HP, Retey JV, Tonz K, Gottselig JM, et al. Caffeine attenuates waking and sleep electroencephalographic markers of sleep homeostasis in humans. Neuropsychopharmacology 2004; 29(10): 1933-9.

36. Ammon HP. Biochemical mechanism of caffeine tolerance. Arch Pharm (Weinheim) 1991; 324(5): 261-7.

37. Chen MD, Lin WH, Song YM, Lin PY, et al. Effect of caffeine on the levels of brain serotonin and catecholamine in the genetically obese mice. Zhonghua Yi Xue Za Zhi (Taipei) 1994; 53(5): 257-61.

38. Montano LM, Carbajal V, Arreola JL, Barajas-Lopez C, et al. Acetylcholine and tachykinins involvement in the caffeine-induced biphasic change in intracellular Ca2+ in bovine airway smooth muscle. Br J Pharmacol 2003; 139(6): 1203-11.

39. Wakade TD, Bhave AS, Bhave SV, Wakade AR. Activation of muscarinic and serotonergic receptors results in phosphoinositide hydrolysis but not in mobilization of calcium in sympathetic neurons. Blood Vessels 1991; 28(1-3): 6-10-

40. Salin-Pascual RJ, Valencia-Flores M, Campos RM, Castano A, et al. Caffeine challenge in insomniac patients after total sleep deprivation. Sleep Med 2006; 7(2):141-5.

41. Murillo-Rodriguez E, Blanco-Centurion C, Gerashchenko D, Salin- Pascual RJ, et al. The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience 2004; 123(2): 361-70.

42. Kamimori GH, Penetar DM, Headley DB, Thorne DR, et al. Effect of three caffeine doses on plasma catecholamines and alertness during prolonged wakefulness. Eur J Clin Pharmacol 2000; 56(8): 537-44.

43. Kurosawa M, Nagata S, Takeda F, Mima K, et al. Effects of caffeine and promazine hydrochloride on plasma catecholamines in thoroughbreds at rest and during treadmill exercise. Equine Vet J Suppl 1999; 30: 596-600.

44. Minana MD, Grisolia S. Caffeine ingestion by rats increases noradrenaline turnover and results in self-biting. J Neurochem 1986; 47(3): 728-32.

45. Boutrel B, Koob GF. What keeps us awake: the neuropharmacology of stimulants and wakefulness-promoting medications. Sleep 2004; 27(6): 1181-94.

46. da Silva RS, Richetti SK, Silveira VG, Battastini AM, et al. Maternal caffeine intake affects acetylcholinesterase in hippocampus of neonate rats. Int J Dev Neurosci 2008; 26(3- 4) 339-43.

47. Bennett HJ, Semba K. Immunohistochemical localization of caffeineinduced c-Fos protein expression in the rat brain. J Comp Neurol 1998; 401(1): 89-108.

48. Deurveilher S, Lo H, Murphy JA, Burns J, et al. Differential c-Fos immunoreactivity in arousal-promoting cell groups following systemic administration of caffeine in rats. J Comp Neurol 2006; 498(5): 667-89.

49. Enslen M, Milon H, Wurzner HP. Brain catecholamines and sleep states in offspring of caffeine-treated rats. Experientia 1980; 36(9): 1105-6.

50. Nehlig A, Boyet S. Dose-response study of caffeine effects on cerebral functional activity with a specific focus on dependence. Brain Res 2000; 858(1): 71-7.

51. Perez V, Sosti V, Rubio A, Barbanoj M, et al. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration. Eur J Pharmacol 2007; 576(1-3): 83-90.

52. Singewald N, Sharp T. Neuroanatomical targets of anxiogenic drugs in the hindbrain as revealed by Fos immunocytochemistry. Neuroscience 2000; 98(4): 759-70.

53. Basheer R, Bauer A, Elmenhorst D, Ramesh V, et al. Sleep deprivation upregulates A1 adenosine receptors in the rat basal forebrain. Neuroreport 2007; 18(18): 1895-9.

54. Elmenhorst D, Meyer PT, Winz OH, Matusch A, et al. Sleep deprivation increases A1 adenosine receptor binding in the human brain: a positron emission tomography study. J Neurosci 2007; 27(9): 2410-15.

55. Salin-Pascual R, Gerashchenko D, Greco M, Blanco-Centurion C, et al. Hypothalamic regulation of sleep. Neuropsychopharmacology 2001; 25(5 Suppl): S21-S27.

56. Salin-Pascual RJ, Upadhyay U, Shiromani PJ. Effects of hypocaloric diet on sleep in young and old rats. Neurobiol Aging 2002; 23(5): 771-6.